Skinvisible

Skinvisible Short-term Debt

The Short-Term Debt of Skinvisible (SKVI) as of Oct 21, 2026 is 700,599.00 USD. In the previous year, Short-Term Debt was 869,625.00 USD — a change of -19.44% (lower).

Short-term Debt

700,599.00USD

YoY

-19.44%

Last updated:

Short-Term Debt of Skinvisible is 2020 700,599.00 USD. Short-Term Debt of Skinvisible was 2019 869,625.00 USD. It decreases by -19.44% lower compared to the previous year.

The Skinvisible Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2014
3.05 M USD
Jan 1, 2015
2.66 M USD
Jan 1, 2016
4.85 M USD
Jan 1, 2017
5.07 M USD
Jan 1, 2018
2.82 M USD
Jan 1, 2019
869,625.00 USD
Jan 1, 2020
700,599.00 USD
The Skinvisible Short-term Debt history
YEARShort-term DebtYoY
700,599.00USD-19.44%
869,625.00USD-69.11%
2.82 MUSD-44.46%
5.07 MUSD+4.44%
4.85 MUSD+82.30%
2.66 MUSD-12.78%
3.05 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Skinvisible Stock analysis

What does Skinvisible do? Skinvisible Inc develops and patents the Invisicare polymer delivery system, which enhances the delivery of active ingredients in topical skin care products. The company has formulated over forty topical skin products using Invisicare, with Pivotal being the patented technology that enables extended duration of active ingredients on the skin. Invisicare specifically carries water-insoluble and certain cationic active ingredients in water-based products without alcohol, silicones, waxes, or organic solvents. The firm's revenue comes from licensing the Invisicare technology to partners who develop and sell skin care products incorporating this delivery system. Skinvisible Inc's primary customers are pharmaceutical and cosmetic companies seeking to improve the efficacy of their topical skin care formulations. These companies purchase the Invisicare technology to integrate into their own product lines, leveraging the extended delivery duration and compatibility with water-based formulations. The company does not sell end-user products but focuses on technology licensing for partners who manufacture and market the final skin care products. The business model relies on the patent protection of Invisicare, which allows Skinvisible to generate revenue through licensing agreements. Partners pay for the right to use the technology in their products, with the company's focus on developing and protecting the polymer delivery system as its core asset. The firm's product portfolio includes over forty topical skin products developed using Invisicare, but these are not sold directly by Skinvisible Inc. Skinvisible is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Skinvisible stock

Short-Term Debt of Skinvisible is 700,599.00 USD in 2020.

Short-Term Debt of Skinvisible changed from 869,625.00 USD to 700,599.00 USD, representing a -19.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt Skinvisible since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's Skinvisible historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Skinvisible

All Key Metrics — Skinvisible